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arge databases obtained in the past decade from registries
nd clinical trials have allowed a better characterization of
he clinical profile of patients admitted to hospitals for
ecompensated heart failure (DHF) (1–3). This new infor-
ation has clearly recognized fluid overload and pulmonary
ongestion as the main reasons for hospitalization in the
reat majority of these patients (1–4). The potential detri-
ental effects of cardiopulmonary congestion and elevated
entricular filling pressure have also been well described (5).
See page 675
hese effects include further neurohormonal activation,
ubendocardial ischemia and cell death by necrosis or
poptosis secondary to increased wall stress and decreased
oronary perfusion, worsening of mitral and tricuspid regur-
itation due to chamber dilation and spherical remodeling
f the ventricles, and impairment of ventricular systolic and
iastolic functions (5). Furthermore, correction of volume
verload has been shown to have a favorable effect on
ymptoms and a positive effect on length of stay, rate of
ehospitalization, and long-term survival (6–8) and should
herefore be an important therapeutic goal. At the same
ime, however, recent publications clearly indicate that this
herapeutic goal is often not achieved, and patients with
HF are frequently discharged with persistent symptoms
nd with minimal or no weight loss or even weight gain
uring the hospital stay (1,7). What is the reason for failure
o achieve therapeutic goals in many patients admitted with
HF? Is it lack of effective therapy or ineffective use of
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.a
From the Heart Failure Program, University of Southern California, Keck School
f Medicine, Los Angeles, California.xisting therapy? The answer to this question is probably
oth.
Non–potassium-sparing diuretics, especially loop diuret-
cs given intravenously, have been the mainstay of therapy
or fluid overload. This therapy is used in the great majority
f patients with DHF (1) and has recently been recom-
ended as the first-line therapy by the 2007 practice
uidelines of the Heart Failure Society of America (9).
lthough these drugs can achieve effective diuresis in the
ajority of patients, their use in patients with DHF may be
imited because of adverse effects such as electrolyte abnor-
alities, neurohormonal stimulation, and worsening of
enal function (10). In addition, refractoriness to diuretics is
ommon in patients with DHF and, therefore, achieving
ffective diuresis often requires aggressive strategies, includ-
ng the use of loop diuretics either in high doses or in
ombination with thiazide diuretics. These practices, how-
ver, have been reported to be associated with worsening
enal function, prolongation of length of stay, and increased
ong-term morbidity and mortality (11,12). Continuous
nfusion of loop diuretics has been shown to have a superior
atriuretic and diuretic effect compared to intermittent
olus injections (13), but this treatment has not been
ommonly used; it should be used more often by clinicians
or correction of fluid overload in patients with DHF.
Vasoactive medications are often used to facilitate diure-
is in patients admitted with volume overload, especially
hose who seem resistant to diuretics. Although the inodi-
ators dobutamine and milrinone have a potent hemody-
amic effect and can significantly augment cardiac output
14), their effect on renal hemodynamics, as well as on urine
utput, in patients with DHF has not been sufficiently
nvestigated and is therefore not clear. In addition, the
dministration of these drugs in hospitalized patients with
HF has been shown, in a number of studies, to be
ssociated with increased risk of long-term morbidity and
ortality (15), and their use has therefore been recom-
ended only in selected patients (9). Renal dose dopamine
as been shown to improve cardiac output, increase renal
lood flow, and augment urine output in a small number of
ymptomatic patients with heart failure (HF) (16). The
dministration of this drug, however, may be associated
ith tachycardia and arrhythmias, and its effects in patients
ith DHF have not been extensively investigated.
Intravenous vasodilators are often used for the treatment
f DHF (1), and recent guidelines have supported their use
n addition to diuretics for rapid improvement of hemody-
amic parameters and congestive symptoms in the absence
f symptomatic hypotension (9). These drugs can effectively
nd rapidly reduce left ventricular (LV) filling pressure by
irtue of their systemic vasodilatory effect, but their effect on
he kidney has not been sufficiently studied (17). The effect
f nitroglycerin on urine output in patients with DHF has
ot been evaluated, and infusion of the drug into the renal
rtery resulted in no significant effect on renal blood flow
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February 13, 2007:684–6 Editorial Comment17). An early study using hemodynamically effective doses
f sodium nitroprusside also showed a significant diuretic
nd natriuretic effect in a small group of patients with HF
18). These potential effects of the drug, however, have not
een further explored. The effect of nesiritide, a B-type
atriuretic peptide, has been studied more extensively than
hat of nitroglycerin and nitroprusside. Most studies, how-
ver, have been limited to small numbers of patients, and
he results have been conflicting (19,20). A recent study
sing nesiritide in a larger number of patients with HF
ndergoing cardiac surgery has demonstrated a superior
ffect on urine output compared with placebo (21). En-
ancement of diuretic effect in this trial, as well as in other
tudies (20), may suggest a relation between the degree of
olume overload and the effect of the drug on urine output.
ore information, however, is needed to explore the effect
f nesiritide on urine output in patients with DHF.
Extracorporeal ultrafiltration (UF) has also been used to
orrect hypervolemia in patients with HF (22). Recent
tudies in relatively small numbers of patients showed that
arly application of newly designed veno-venous UF was
easible and well tolerated in patients with DHF and
llowed a significant removal of fluid (23,24). This treat-
ent resulted in symptomatic and hemodynamic improve-
ent, as well as improvement in neurohormonal profile
22–24). In this issue of the Journal, Costanzo et al. (25)
eport the results of the first large-scale randomized study
UNLOAD [Ultrafiltration Versus Intravenous Diuretics
or Patients Hospitalized for Acute Decompensated Con-
estive Heart Failure]) designed to assess the efficacy and
afety of UF for the treatment of patients with DHF. In this
tudy, 200 patients hospitalized for DHF secondary to left
entricular systolic dysfunction were randomized to either
arly UF (within 24 h of hospitalization) or to intravenous
iuretics. The study clearly showed the efficacy and safety of
F in correcting fluid overload in a patient population with
mean net fluid loss of 4.6 l at 48 h without a significant
hange in serum creatinine or blood pressure. The study also
emonstrated the clinical benefit of aggressive fluid removal
n this patient population. A superior fluid loss achieved
ith UF compared to intravenous diuretics at the dose used
n the study (4.6 vs. 3.3 l, p 0.001) had a lasting effect and
educed the rate of rehospitalizations and unscheduled visits
or 3 months after discharge. These data suggest that a rapid
orrection of volume overload with a careful and frequent
onitoring of volume status and renal function is both safe
nd effective in patients with DHF.
It is interesting to note that a larger net fluid loss
emonstrated in the UNLOAD study with UF compared to
iuretics did not have an impact on length of stay. This
nding should provide an important lesson to both clini-
ians and investigators and suggests that length of hospital
tay in patients with DHF is often determined by multiple
actors, some of them unrelated to patient response to
herapy. These factors include adjustment of HF therapy
efore discharge, performance of diagnostic and therapeuticrocedures (echocardiogram, myocardial perfusion studies,
agnetic resonance imaging, cardiac catheterization, percu-
aneous or surgical coronary interventions, cardioversion,
tc.), treatment of comorbidities, social issues related to
lacement of patients after discharge, and lack of well-
efined criteria and protocols for hospital discharge.
Should UF replace intravenous diuretics as a first-line
herapy for patients with hypervolemia admitted for DHF?
lthough there are potential theoretical advantages to
emoval of excess volume with UF compared to diuretics
25), the validity of such a concept needs to be proven in
arger studies designed to compare efficacy, safety, and
ost-effectiveness of a comparable net fluid loss with these 2
herapeutic modalities in patients with DHF due to both
ystolic and diastolic LV dysfunction. The results of the
NLOAD trial, however, clearly demonstrate a great po-
ential for the use of UF in patients with DHF who are
ither resistant to diuretics or demonstrate unfavorable side
ffects. An early application of this technology in such
atients should allow effective therapy, prevention of ad-
erse events, and improvement of after-discharge outcome.
In summary, clinical congestion due to volume overload is
he main cause of hospitalization for patients with HF and
s an important therapeutic target. Recent information
uggests failure to achieve effective and rapid correction of
his condition in many patients hospitalized for DHF,
hich results in prolongation of hospital stay and thus
ignificant effect on quality of life, increased cost of therapy,
nd unfavorable after-discharge outcome. The results of the
NLOAD study suggest that UF is a safe and effective
herapeutic modality for correction of volume overload in
ospitalized patients with DHF due to LV systolic dysfunc-
ion. The use of this therapy should be considered early in
atients not responding to intravenous diuretics and vaso-
ctive medications and in patients in whom such therapy is
iscontinued or reduced because of worsening renal func-
ion or other drug-induced complications. A structured
herapeutic approach to correction of fluid overload, includ-
ng diuretics, vasoactive medications, and UF, should assure
rapid correction of LV filling pressure and cardiopulmo-
ary congestion, and thus early improvement of symptoms,
hortening of length of stay, and reduction in the need for
ehospitalizations in this patient population.
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